Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Quince Therapeutics ( (QNCX) ) is now available.
On January 30, 2026, Quince Therapeutics, Inc. announced that five members of its Board of Directors—Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray—resigned from their positions effective the same day. The company stated that these departures were not due to any disagreements regarding its operations, policies, or practices, suggesting a non-contentious board transition with limited immediate operational disruption indicated for stakeholders.
The most recent analyst rating on (QNCX) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Average Trading Volume: 1,873,389
Technical Sentiment Signal: Sell
Current Market Cap: $9.47M
See more data about QNCX stock on TipRanks’ Stock Analysis page.